These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 29610318)
1. Ablation of insulin receptor substrates 1 and 2 suppresses Xu H; Lee MS; Tsai PY; Adler AS; Curry NL; Challa S; Freinkman E; Hitchcock DS; Copps KD; White MF; Bronson RT; Marcotrigiano M; Wu Y; Clish CB; Kalaany NY Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4228-4233. PubMed ID: 29610318 [TBL] [Abstract][Full Text] [Related]
2. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899 [TBL] [Abstract][Full Text] [Related]
3. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells. Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007 [TBL] [Abstract][Full Text] [Related]
5. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631 [TBL] [Abstract][Full Text] [Related]
6. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer. Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173 [TBL] [Abstract][Full Text] [Related]
7. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500 [TBL] [Abstract][Full Text] [Related]
8. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493 [TBL] [Abstract][Full Text] [Related]
9. Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer. Chen R; Sweet-Cordero EA Cancer Discov; 2013 May; 3(5):491-3. PubMed ID: 23658296 [TBL] [Abstract][Full Text] [Related]
10. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. Morel M; Long W Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945 [TBL] [Abstract][Full Text] [Related]
11. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis. Green S; Trejo CL; McMahon M Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140 [TBL] [Abstract][Full Text] [Related]
12. Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma. Metz HE; Kargl J; Busch SE; Kim KH; Kurland BF; Abberbock SR; Randolph-Habecker J; Knoblaugh SE; Kolls JK; White MF; Houghton AM Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8795-800. PubMed ID: 27439864 [TBL] [Abstract][Full Text] [Related]
14. AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer. Tien JC; Chugh S; Goodrum AE; Cheng Y; Mannan R; Zhang Y; Wang L; Dommeti VL; Wang X; Xu A; Hon J; Kenum C; Su F; Wang R; Cao X; Shankar S; Chinnaiyan AM Proc Natl Acad Sci U S A; 2021 May; 118(20):. PubMed ID: 33972443 [TBL] [Abstract][Full Text] [Related]
15. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929 [TBL] [Abstract][Full Text] [Related]
16. IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Wang YA; Sun Y; Palmer J; Solomides C; Huang LC; Shyr Y; Dicker AP; Lu B Mol Cancer Res; 2017 Jul; 15(7):896-904. PubMed ID: 28330997 [TBL] [Abstract][Full Text] [Related]
17. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism. Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738 [TBL] [Abstract][Full Text] [Related]
18. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230 [TBL] [Abstract][Full Text] [Related]
19. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913 [TBL] [Abstract][Full Text] [Related]
20. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines. Dogan Turacli I; Ozkan AC; Ekmekci A Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]